Loading...
XSHE300725
Market cap789mUSD
Jan 10, Last price  
29.11CNY
1D
-3.45%
1Q
-16.11%
IPO
274.16%
Name

PharmaBlock Sciences Nanjing Inc

Chart & Performance

D1W1MN
XSHE:300725 chart
P/E
29.34
P/S
3.36
EPS
0.99
Div Yield, %
0.34%
Shrs. gr., 5y
1.56%
Rev. gr., 5y
29.25%
Revenues
1.73b
+8.18%
58,547,36276,639,124136,130,804188,377,858273,250,557478,254,313662,230,9331,022,229,2151,201,629,0701,594,699,9781,725,203,986
Net income
197m
-37.19%
18,247,14222,471,46119,934,48936,115,20667,179,202133,363,374152,068,782184,207,681486,559,403314,223,824197,360,947
CFO
247m
+0.09%
18,316,10011,909,55427,524,48422,757,68854,639,657160,161,084127,044,730271,505,518238,029,950246,608,762246,839,976
Dividend
Jun 14, 20240.31 CNY/sh
Earnings
May 16, 2025

Profile

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.
URL
https://www.pharmablock.com/
IPO date
Nov 10, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,725,204
8.18%
1,594,700
32.71%
Cost of revenue
1,279,067
1,150,713
Unusual Expense (Income)
NOPBT
446,137
443,987
NOPBT Margin
25.86%
27.84%
Operating Taxes
24,014
Tax Rate
5.38%
NOPAT
422,123
443,987
Net income
197,361
-37.19%
314,224
-35.42%
Dividends
(19,966)
(19,966)
Dividend yield
0.25%
0.12%
Proceeds from repurchase of equity
(20,033)
BB yield
0.25%
Debt
Debt current
609,917
180,693
Long-term debt
1,138,942
1,392,373
Deferred revenue
51,737
52,400
Other long-term liabilities
900
450
Net debt
142,577
259,341
Cash flow
Cash from operating activities
246,840
246,609
CAPEX
(315,775)
Cash from investing activities
Cash from financing activities
65,371
760,361
FCF
331,178
(463,135)
Balance
Cash
1,600,799
1,313,725
Long term investments
5,483
Excess cash
1,520,022
1,233,990
Stockholders' equity
1,928,077
1,733,439
Invested Capital
3,113,523
3,039,165
ROIC
13.72%
17.24%
ROCE
9.58%
10.34%
EV
Common stock shares outstanding
201,389
200,143
Price
39.25
-51.24%
80.50
-43.38%
Market cap
7,904,507
-50.94%
16,111,476
-43.17%
EV
8,047,084
16,370,817
EBITDA
562,224
532,017
EV/EBITDA
14.31
30.77
Interest
68,198
45,721
Interest/NOPBT
15.29%
10.30%